BIOLINERX     Print Page  Close Window

SEC filings
BIOLINERX LTD. filed this Form 424B5 on 07/26/2017
Entire Document

We may sell the securities offered under this prospectus in one or more of the following ways (or in any combination) from time to time:
to or through one or more underwriters or dealers;
in short or long transactions;
directly to investors; or
through agents.
If underwriters or dealers are used in the sale, the securities will be acquired by the underwriters or dealers for their own account and may be resold from time to time in one or more transactions, including:
in privately negotiated transactions;
in one or more transactions at a fixed price or prices, which may be changed from time to time;
in “at the market offerings,” within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise;
at prices related to those prevailing market prices; or
at negotiated prices.
As applicable, we and our respective underwriters, dealers or agents, reserve the right to accept or reject all or part of any proposed purchase of the securities. We will set forth in a prospectus supplement the terms and offering of securities by us, including:
the names of any underwriters, dealers or agents;
any agency fees or underwriting discounts or commissions and other items constituting agents’ or underwriters’ compensation;
any discounts or concessions allowed or reallowed or paid to dealers;
details regarding over-allotment options under which underwriters may purchase additional securities from us, if any;
the purchase price of the securities being offered and the proceeds we will receive from the sale;
the public offering price; and
the securities exchanges on which such securities may be listed, if any.
We may enter into derivative transactions with third parties or sell securities not covered by this prospectus to third parties in privately negotiated transactions from time to time. If the applicable prospectus supplement indicates, in connection with those derivative transactions, such third parties (or affiliates of such third parties) may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, such third parties (or affiliates of such third parties) may use securities pledged by us, or borrowed from us, or others to settle those sales or to close out any related open borrowings of securities, and may use securities received from us in settlement of those derivative transactions to close out any related open borrowings of securities. The third parties (or affiliates of such third parties) in such sale transactions by us will be underwriters and will be identified in an applicable prospectus supplement (or a post-effective amendment).